𝔖 Bobbio Scriptorium
✦   LIBER   ✦

MDR1polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer

✍ Scribed by Bernard Paule; Vincent Castagne; Véronique Picard; Raphaël Saffroy; René Adam; Catherine Guettier; Robert Farinotti; Laurence Bonhomme-Faivre

Book ID
107576962
Publisher
Springer US
Year
2009
Tongue
English
Weight
210 KB
Volume
27
Category
Article
ISSN
1357-0560

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Insulin-like growth factor 1 expression
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan
✍ Mario Scartozzi; Alessandra Mandolesi; Riccardo Giampieri; Chiara Pierantoni; Fo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 245 KB

## Abstract Seventy to 40% of K‐RAS wild type colorectal tumors does not seem to benefit from treatment with antiepidermal growth factor receptor (anti‐EGFR) monoclonal antibodies. Recent data suggested that in presence of IGF‐1 system, altered activation colorectal cancer cells may escape anti‐EGF

Bevacizumab in association with de Gramo
Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer : A single-center phase 2 trial
✍ Bruno Vincenzi; Daniele Santini; Antonio Russo; Chiara Spoto; Olga Venditti; Sim 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

## Abstract ## BACKGROUND: The aim of the current study was the investigation of the value of bevacizumab + 5‐fluorouracil(5–FU)/folinic acid in patients with advanced colorectal cancers who have exhausted standard chemotherapy options. ## METHODS: The authors included 48 heavily pretreated pati